- Home
- CELC vs RYN Comparison
CELC vs RYN Comparison
Compare CELC & RYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | RYN |
|---|---|---|
| Founded | 2011 | 1926 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CELC | RYN |
|---|---|---|
| Price | $110.32 | $23.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $100.13 | $27.00 |
| AVG Volume (30 Days) | 629.3K | ★ 1.7M |
| Earning Date | 11-12-2025 | 02-11-2026 |
| Dividend Yield | N/A | ★ 12.04% |
| EPS Growth | N/A | ★ 373.89 |
| EPS | N/A | ★ 5.07 |
| Revenue | N/A | ★ $1,293,371,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.39 |
| Revenue Growth | N/A | ★ 60.70 |
| 52 Week Low | $7.58 | $21.06 |
| 52 Week High | $116.44 | $28.31 |
Technical Indicators
Market Signals| Indicator | CELC | RYN |
|---|---|---|
| Relative Strength Index (RSI) | 60.08 | 59.89 |
| Support Level | $103.00 | $22.93 |
| Resistance Level | $112.69 | $24.82 |
| Average True Range (ATR) | 6.44 | 0.68 |
| MACD | 0.07 | 0.15 |
| Stochastic Oscillator | 70.07 | 73.89 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About RYN Rayonier Inc. REIT
Rayonier owns and manages over 2 million acres of timberland in the United States. It is one the largest private landowners in North America. Rayonier is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities.